Shiyao Group's antibody drug conjugate SYS6023 has been approved for clinical trials in the United States

On July 8th, Shiyao Group announced that the experimental new drug (IND) application for the antibody drug conjugate SYS6023 developed by its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has been approved by the US Food and Drug Administration (FDA) and can be used for clinical trials in the United States.

On July 8, 2024, Shiyao Group announced that the experimental new drug (IND) application for the antibody drug conjugate SYS6023 developed by its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has been approved by the US Food and Drug Administration (FDA) and can undergo clinical trials in the United States. Previously, the product had been approved by the National Medical Products Administration of the People's Republic of China in March 2024 and could undergo clinical trials in China.

The continuous monitoring system of Borong Environment adopts a wireless architecture for implementation and stable operation.

With unique transmission stability and data redundancy, it ensures data integrity in catastrophic situations, scalable architecture, and excellent system performance, providing a strong foundation for cost reduction, efficiency improvement, stable operation, and convenient and rapid implementation of later supplementary monitoring point construction, installation, and verification. Customers can efficiently provide support when facing quality audits such as those conducted by the European Union.